Two nonprofit groups released a report last week that calculated the cost to consumers of pay-for-delay deals that delayed the release of cheaper, generic versions of brand name drugs, estimating that cost to be $98 billion. Public interest and consumer advocacy groups MassPirg and Community Catalys released the report last Thursday. The report says consumers paid an average of 10 times more for the brand name drugs. The release, entitled “Top Twenty pay-For-Delay Drugs: How Drug Industry Payoffs delay Generics, Inflate Prices and Hurt Consumers,” found generic releases were delayed by an average of five years as consumers played inflated prices. The US Supreme Court ruled last month that the schemes can violate antitrust law and are anticompetitive in a case initiated by the Federal Trade Commission against brand name drug maker Actavis. Click the link below to read the full report.
Full Content: Masspirg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Nominates Olivia Trusty for FCC Commissioner Role Ahead of Inauguration
Jan 16, 2025 by
CPI
Lawyers Claim eXp’s Settlement Tactics Hurt Antitrust Case Potential
Jan 16, 2025 by
CPI
Amex GBT Pushes Back Against DOJ Lawsuit Over CWT Acquisition
Jan 16, 2025 by
CPI
Belgium Opens Antitrust Probe into AB InBev’s Market Practices
Jan 16, 2025 by
CPI
Tech Groups Sue CFPB Over New Rule on Digital Wallet Oversight
Jan 16, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand